Researchers from University College London have discovered that the widely used antiinflammatory drug HUMIRA doesn't just work by inhibiting its target protein, TNF, but by enhancing a particular ...

April 29 (Reuters) - AbbVie on Wednesday reported better-than-expected quarterly revenue and profit, fueled by demand for ...

AbbVie ABBV stock has risen 8.0% in six months, adding more than $24 billion to its market value. AbbVie has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, by ...

LONDON, May 25 (Reuters) - Belgian drugmaker UCB is to test its rheumatoid arthritis drug Cimzia in a head-to-head clinical trial against Abbott's Humira, as competition heats up in the market. Humira ...

SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars are gradually making inroads in the outpatient drug ...

The collaboration will make lower‑cost biosimilar alternatives to Humira and Stelara available to commercial members.

More than 300,000 Americans use a medication called Humira. Most of them are paying far too much for it. Humira, the brand name of AbbVie’s adalimumab, is prescribed to treat inflammatory diseases ...

The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...

Humira's continued dominance after losing patent protection is one example of why the system for distributing drugs is broken. More than 300,000 Americans use a medication called Humira. Most of them ...